New hope for rare gut tumors? phase 2 trial launches

NCT ID NCT07640737

Not yet recruiting Disease control Sponsor: Aurigene Discovery Technologies Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily until their disease progresses or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AUR103 calcium
What this could lead to: If successful, this could point toward a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to other therapies.
What could go wrong: This is an early phase 2 proof-of-concept study with only 30 participants. It may not show enough benefit to move forward, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NET OF GI ORIGIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 neoplasm neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NET OF GI ORIGIN NEUROENDOCRINE (NE) TUMORS

Contacts and locations

Show contact details

Locations

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Hoag Family Cancer Institute

Newport Beach, California, 92657, United States
Mayo Clinic Cancer Center (MCCC)

Phoenix, Arizona, 85054, United States
Mayo Clinic Cancer Center (MCCC)

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••
Mayo Clinic Hospital - Florida

Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.